Open Orphan Share Discussion Threads

[malcolmmm] 09/12/2020 17:20

Maybe Cathal will infer that they are very near a deal concerning the wearables, wouldn't surprise me

[troutisout] 09/12/2020 16:34

judijudi,
What selling?

[judijudi] 09/12/2020 15:16

Thank you Chaps

[gregb] 09/12/2020 15:13

https://www.openorphan.com/investors/key-dates-calender:-)

[judijudi] 09/12/2020 15:08

Surprised we are not down with the selling 🤷‍a94;️

[judijudi] 09/12/2020 14:56

m5
I hope he has something new to say and it’s not just a rehash of the last couple of interviews
Any chance you could post me the link to register please

[supernumerary] 09/12/2020 14:50

If you're being literal, yes it's false choice, but the risk doesn't go away does it? The vaccine is well tested (40,000+ patients is hardly a small trial), has so far raised no concerns, yesterday had a couple of people with allergic reactions that were quickly dealt with, and seems to be very effective.

I think instead of giving it away free, they should charge a few hundred quid for it, then everyone would be clamouring for it - Veblen goods in action!

[pierre oreilly] 09/12/2020 14:31

But that's a false choice. i.e. if you don't have the vaccine you don't necessarily get covid. (everyone on the planet would already have it if that were the case).

My personal choice on whether to have the jab is easy because it'll be a long time before i'm offered it, by which time i hope it will be proven safe and effective. But if i were an 80 year old still with my marbles, i would have refused it yesterday, and probably for a few more days before i'd estimate the risk of the jab less than the (high in that case) deathly risk from covid. To my amateur understanding, this vaccine is a completely new way of working, so there are some (zero or more) unknowable risks.

[supernumerary] 09/12/2020 14:21

Haven't seen the detail of the protocol, nor the results, although obviously understand in principle. But I know for certain I'd sooner take the vaccine than get the disease, so it's a pretty easy choice for me.

[pierre oreilly] 09/12/2020 13:55

9163

Super - billions at stake. Although presented as scientific studies, some science is more equal than others.

Judging by what someone in the bizz posted about the particular very short phase 3 for the Pfizer vaccine a couple of weeks ago, it doesn't surprise me that some things were 'missed' and some questions not asked (iirc, it was mainly self reporting via phone calls to speed things up).

It's why i said doctors on the front line would have difficult decisions to make in deciding whether or not to be one of the first to get the jab (since they probably realise a rushed study is risky).

Not to worry, yump came to explain drs would have no worries whatsoever since the vaccine is perfectly safe and furthermore, everyone knows it is. But then again, he is a bit intellectually challenged.

[supernumerary] 09/12/2020 13:52

rovi - so it is a bit odd. In the US 1 in 100 people are reckoned to carry an epipen, so with 20K in the trial you'd expect at least 200 with prior allergies to have been given the vaccine.

I don't think they were specifically excluded, so maybe they self-selected themselves out, which given their history wouldn't be that surprising.

[pierre oreilly] 09/12/2020 13:48

Of course a challenge study would possibly gain data on reactions. That's not the primary purpose, but they obviously monitor every effect in the study. The selection of participants would try to rule out anyone not 100% fit or those with allergic reactions - which is why if there are any allergic reactions to the vaccine it would be valuable data, and certainly input into a phase 3/to market decision. You obviously can't say 'there'll be no bad reactions' after a cs if there were none in the cs, but you can certainly say 'bad reactions are a concern' if there are any bad reactions to the vaccine in the demographic of the participants.

I'd say immediate authorisation of phase 3 or going to market would be postponed pending further study if there were any allergic reactions at all during a challenge study (even though the cs isn't explicitly looking for them).

[rovi70] 09/12/2020 13:39

target was 5000

[supernumerary] 09/12/2020 13:08

I'm somewhat surprised this didn't appear earlier given that they've already trialled with over 20,000 patients. I wonder how many people they gave it to yesterday?

[lazarus2010] 09/12/2020 13:04

trout...to add to your excellent attempts at clarification, and to answer imho one of the above points, I doubt very much that they would deliberately vaccinate and infect a patient with high allergy level as:

1. the risks would be too great that it might cause either fatal or at least serious reaction and

2. they clearly state that CHIM volunteers should be under 30 (18-30 I think?) and healthy, so this would exclude allergy sufferers - imho.

[troutisout] 09/12/2020 12:52

As above, the allergic reactions and side effects are due to the vaccine and therefore don't need a CHIM or even exposure to Covid. The vaccine is the thing that causes the allergic reaction/side effect, the vaccine cannot spread outside of who it is injected into. So tests can be done on that anywhere.
CHIMs are used to test things that you don't want out spreading in the general population, hence the isolation facility.

[judijudi] 09/12/2020 12:48

Surely the Chims are to pick up on things like allergic reactions and other side effects and not just vaccine effectiveness

[troutisout] 09/12/2020 12:48

You are missing something, try posts 9148 and 9152.

Challenge studies are expensive, they are used on Humans in an isolation facility for a reason, the things you are giving them are not to leave that facility, viruses, bacteria, etc.

Allergic reactions can be tested by just giving people with different allergies the vaccine (perhaps in differing doses), however the vaccine is currently being administered to the general population, so these tests do not need to be done in a secure, isolation facility.

The Covid CHIMs will require the patients who have had the vaccine/variant of vaccine to be 'infected' with the designed dosage of Covid19 to test the efficacy of the Vaccine.

[lako42] 09/12/2020 12:32

Am I missing something? I don't think anyone has related ORPH's business to the allergic reactions news, it's very topical though.

[m5] 09/12/2020 12:06

Registered for tonight. CF is on at 18.55pm

[malcolmmm] 09/12/2020 12:04

Well perhaps they will now challenge test those with allergies along with the rest

[troutisout] 09/12/2020 11:52

Have to agree with the above Covid CHIMs are only useful for working out the vaccines effectiveness against Covid. For allergic reactions, etc wider trials are needed (you don't need to isolate patients in a CHIM study for that). Stage 2 and 3 should have covered this.
Not sure how any bad reaction news story is a boost to ORPH's share price Suggest you understand what OPRH's offering is to these vaccines and the fact there is a limit to how many they can actually do at one time. They have enough planned! The smooth rollout of vaccinations is far more likely to lead to more CHIM testing, looking at next gen vaccines, hybrids and dosing changes.